Valproate metabolism during valproate-associated hepatotoxicity in a surviving adult patient

Epilepsy Research

Volumn 41, Issue 3, 2000, Pages 259-268

  McLaughlin, Daniel B ^a   Eadie, Mervyn J ^a   Parker Scott, Suzanne L ^a   Addison, Russell S ^a   Henderson, Robert D ^b   Hooper, Wayne D ^a   Dickinson, Ronald G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Clin Sci Bldg Roy Brisbane H ^*  (Australia)

Author keywords

Oxidation; Anticonvulsants; Hepatotoxicity; Metabolism; Valproate

Indexed keywords

VALPROIC ACID;

ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; EPILEPSY; HUMAN; LIVER FUNCTION; LIVER TOXICITY; PRIORITY JOURNAL;

ADULT; ANTICONVULSANTS; BIOTRANSFORMATION; ELECTROENCEPHALOGRAPHY; EPILEPSIES, PARTIAL; HEPATITIS, TOXIC; HUMANS; LIVER FUNCTION TESTS; MALE; TOMOGRAPHY, X-RAY COMPUTED; VALPROIC ACID;

EID: 0034308080     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(00)00151-0     Document Type: Article

References (27)

1. Baillie T.A. Metabolic activation of valproic acid and drug-mediated hepatotoxicity: role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chem. Res. Toxicol. 1:1988;195-199.
2. Bjorge S.M., Baillie T.A. Studies on the beta-oxidation of valproic acid in rat liver mitochondrial preparations. Drug Metab. Dispos. 19:1991;823-829.
3. Bryant A.E., Dreifuss F.E. Valproic acid hepatic fatalities: III: US experience since 1986. Neurology. 46:1996;465-469.
4. Daum R.S., Mamer O.A., Lamm P.H., Scriver P.R. A 'new' disorder of isoleucine catabolism. Lancet. ii:1971;1289-1290.
5. Davis R., Peters D.H., McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 47:1994;332-372.
6. Dickinson R.G., Hooper W.D., Dunstan P.R., Eadie M.J. Urinary excretion of valproate and some metabolites in chronically treated patients. Ther. Drug Monit. 11:1989;127-133.
7. Dreifuss F.E., Langer D.H., Moline K.A., Maxwell K.E. Valproic acid hepatic fatalites: II: US experience since 1984. Neurology. 39:1989;201-207.
8. Dreifuss F.E., Santilli N., Langer D.H. et al. Vaplroic acid hepatic fatalities: a retrospective review. Neurology. 36:1987;379-385.
9. Eadie M.J., Hooper W.D., Dickinson R.G. Valproate-associated hepatotoxicity and its biochemical mechanisms. Med. Toxicol. 3:1988;85-106.
10. Eadie M.J., McKinnon G.E., Dunstan P.R., MacLaughlin D., Dickinson R.G. Valproate metabolism during hepatotoxicity associated with the drug. Quart. J. Med. 77:1990;1229-1240.
11. Fisher E., Wittfoht W., Nau H. Quantitative determination of valproic acid and 14 metabolites in serum and urine by gas chromatography/mass spectrometry. Biomed. Chromatogr. 6:1992;24-29.
12. Gerber N., Dickinson R.G., Harland R.C. et al. Reye-like syndrome associated with valproic acid therapy. J. Pediatr. 95:1979;142-145.
13. Granneman G.R., Marriott T.B., Wang S.I., Sennello L.T., Hagen N.S., Sonders R.C. Aspects of the dose-dependent metabolism of valproic acid. Levy R.H., Pitlick W.H., Eichelbaum M., Meijer J. Metabolism of Antiepileptic Drugs. 1984;97-104 Raven Press, New York.
14. Hooper W.D., Franklin M.E., Glue P. et al. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of β-oxidation. Epilepsia. 37:1996;91-97.
15. Katayama H., Watanabe M., Yoshitomi H. et al. Urinary metabolites of valproic acid in epileptic patients. Biol. Pharm. Bull. 21:1998;304-307.
16. Keulen F.P., Kochen W. Hepatotoxizität unter valproinsäure behandlung. Klin. Pädiatr. 197:1985;431-436.
17. Kochen W., Schneider A., Ritz A. Abnormal metabolism of valproic acid in severe hepatic failure. Eur. J. Pediatr. 141:1983;30-35.
18. König A., Siemes H., Blaker F. et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalaties. Epilepsia. 35:1994;1005-1015.
19. Kuhara T., Inoue Y., Matsumoto M. et al. Altered metabolic profiles of valproic acid in a patient with Reye's syndrome. Clin. Chim. Acta. 145:1985;135-142.
20. Kuhara T., Inoue Y., Matsumoto M. et al. Markedly increased ω-oxidation of valproate in fulminant hepatic failure. Epilepsia. 31:1990;214-217.
21. McLaughlin, D.B., Andrews, J.A., Hooper, W.D., Cannell, G.R., Eadie, M.J., Dickinson, R.G., 2000, Apparent autoinduction of valproate β-oxidation in humans, Br. J. Clin. Pharmacol. (In press).
22. Rettenmeier A.W., Howald W.N., Levy R.H. et al. Quantitative metabolic profiling of valproic acid in humans using automated gas chromatographic/mass spectrometric techniques. Biomed. Environ. Mass Spectrom. 18:1989;192-199.
23. Rettie A.E., Sheffels P.R., Korzekwa K.R. et al. CYP4 isozyme specificity and the relationship between ω- hydroxylation and terminal desaturation of valproic acid. Biochemistry. 34:1995;7889-7895.
24. Sherratt H.S.A., Osmundsen H. On the mechanisms of some hypoglycaemic actions of the hypoglycaemic toxins hypoglycin and pent-4-enoic acid: a way out of the present confusion. Biochem. Pharmacol. 25:1976;743-750.
25. Siemes H., Nau H., Schultze K. et al. Valproate (VPA) metabolites in various clinical conditions of probable valproate-associated hepatotoxicity. Epilepsia. 34:1993;332-346.
26. Tennison M.B., Miles M.V., Pollack G.M., Thorn M.D., Dupuis R.E. Valproate metabolites and hepatotoxicity in an epileptic population. Epilepsia. 29:1998;543-547.
27. Zimmerman H.J., Ishak K.G. Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology. 2:1982;591.